For ischemic brain damage, is preclinical evidence of neuroprotection by presynaptic blockade of glutamate release enough?
Some drugs blocking glutamate release produce reduced brain injury in some animal models of cerebral ischemia whereas others lack a clear effect. Meta-analysis is a widely used technique in clinical and epidemiological studies. However, it has never been used in the analysis of preclinical studies. In order to estimate quantitatively the current state of the knowledge concerning the neuroprotective effect of drugs inhibiting glutamate release and to attempt to resolve the apparent controversy in relation to the neuroprotective properties of these drugs, a meta-analysis was performed. It identified a significant difference between drugs blocking glutamate release and controls. Therefore, we hypothesize that inhibition of presynaptic glutamate release could be a major goal in neuroprotection when ischemic brain damage is present and that meta-analysia could be a useful tool for preclinical studies,
Nava-Ocampo
A A
AA
Unit of Medical Research in Pharmacology, Hospital de Especialidades, Centro Médico Nacional Siglo XXI, IMSS, Morelos, Mexico.
Reyes-Pérez
H
H
Bello-Ramírez
A M
AM
Mansilla-Olivares
A
A
Ponce-Monter
H
H
D002545:Brain Ischemia / Q000378:metabolism*; D018698:Glutamic Acid / Q000378:metabolism*; D006801:Humans; D015201:Meta-Analysis as Topic; D018696:Neuroprotective Agents / Q000494:pharmacology*; D013569:Synapses / Q000187:drug effects*
D018696:Neuroprotective Agents; D018698:Glutamic Acid